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Abstract
Background: Antibiotic exposure rapidly selects for more resistant bacterial strains, and both a drug’s chemical structure
and a bacterium’s cellular network affect the types of mutations acquired.
Methodology/Principal Findings: To better characterize the genetic determinants of antibiotic susceptibility, we exposed a
transposon-mutagenized library of Escherichia coli to each of 17 antibiotics that encompass a wide range of drug classes
and mechanisms of action. Propagating the library for multiple generations with drug concentrations that moderately
inhibited the growth of the isogenic parental strain caused the abundance of strains with even minor fitness advantages or
disadvantages to change measurably and reproducibly. Using a microarray-based genetic footprinting strategy, we then
determined the quantitative contribution of each gene to E. coli’s intrinsic antibiotic susceptibility. We found both loci
whose removal increased general antibiotic tolerance as well as pathways whose down-regulation increased tolerance to
specific drugs and drug classes. The beneficial mutations identified span multiple pathways, and we identified pairs of
mutations that individually provide only minor decreases in antibiotic susceptibility but that combine to provide higher
tolerance.
Conclusions/Significance: Our results illustrate that a wide-range of mutations can modulate the activity of many cellular
resistance processes and demonstrate that E. coli has a large mutational target size for increasing antibiotic tolerance.
Furthermore, the work suggests that clinical levels of antibiotic resistance might develop through the sequential
accumulation of chromosomal mutations of small individual effect.
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Introduction
Antibiotic tolerance, the decreased efficacy of antimicrobial
agents in eliminating infections, is a serious and worsening global
problem in human health [1,2]. During the long history of
chemical warfare between microbes, the genomes of many
bacteria have evolved to encode multiple counter-measures [3].
Moreover, a level of antibiotic tolerance that allows some bacteria
to survive an initial exposure gives the population the opportunity
to accumulate mutations, leading to higher levels of tolerance and
potentially to full clinical resistance [4]. Much of the literature on
antibiotic resistance focuses on tolerance to the high antibiotic
levels typically used in a clinical setting (see [5] for an exception).
Even in clinical practice, however, bacteria commonly experi-
ence sub-inhibitory drug concentrations, which may be capable of
reducing the growth rate but are lower than the minimum
inhibitory concentration (MIC). The cyclical dosing regimen for
most antibiotics, for example, may cause the drug’s plasma
concentration to approach the MIC for short intervals during
treatment. Furthermore, micro-niches within the host, such as
epidermis, lungs, and joints, may attain significantly lower drug
concentrations than the plasma [6]. Finally, patient non-
compliance with the prescribed frequency and duration of
antibiotic use can allow plasma levels to fall below the MIC. In
such circumstances, selection for more tolerant variants is strong.
Outside clinical settings, environments containing antibiotics,
especially at sub-inhibitory concentrations, abound. Soil contains
numerous antibiotic-producing species [7], which generate
compounds with roles in killing competitors as well as in inter-
and intra-species signaling [8]. Antibiotics also enter the soil
through the use of manure from livestock whose feed was
supplemented with antibiotics [9], and wastewater can contain
multiple drugs at concentrations in the range of ng/L, even after
treatment [10]. The rise in environmental antibiotic levels
resulting from the widespread use of antibiotics has selected for
resistant strains in both soil [11] and aqueous [12] environments.
Diverse mechanisms including drug target modification,
enzymatic drug inactivation, and intracellular drug concentration
reduction can lead to antibiotic resistance [13,14,15]. A variety of
sources, such as lateral gene transfer and chromosomal mutations,
can provide the underlying genetic changes, and clinically resistant
strains often contain multiple alterations. The plasmids, transpo-
sons, and mobile chromosome cassettes that contribute to
antibiotic resistance, including methicillin resistance, in Staphylo-
coccus aureus are examples of well-studied extrinsic elements that
confer antibiotic resistance [16]. Similarly, E. coli strains can
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mutations as well as a reduction in outer membrane porins and an
increase in drug efflux pump activity [17]. Cases where multiple
mutations work collectively to give resistance, while of clear
importance, are not well understood, in part because the range of
mutations that can increase a particular bacterium’s antibiotic
tolerance is rarely known.
The effect of mutation in altering genetic programs and
modulating susceptibility, however, is starting to receive attention.
Multiple groups have assayed the drug susceptibility of bacteria
containing families of simple genetic perturbations such as single
gene deletions or transposon insertions [18,19,20,21,22]. These
studies found that large numbers of genes influence drug
susceptibility, including many whose dominant function is not
resistance. Moreover, while some genes, such as those that code
for drug efflux pumps, contribute to resistance to a wide range of
compounds, many others are drug or drug class specific.
Most previous work focused on identifying genes whose removal
changes the MIC by some predetermined threshold, usually 2-fold.
The increasing number of examples of multiple genetic perturba-
tions combining to confer high levels of resistance [23,24],
however, suggests that mutations of even mild individual benefit
are of potential clinical relevance. As such, we decided to take a
complementary approach to identifying mutations that alter
antibiotic susceptibility.
Rather than testing MIC directly, we searched a library of
transposon-mutagenized cells [25] for those with a competitive
advantage at drug concentrations that moderately reduced the
parental strain’s growth rate. Competitive growth of the mutants
for multiple generations caused the abundance of strains with even
minor fitness advantages or disadvantages to change measurably
and reproducibly. Applying microarray-based genetic footprinting
[25] to the resulting population allowed us to identify and quantify
the genetic determinants contributing to both antibiotic sensitivity
and tolerance.
The experimental conditions proved to be particularly condu-
cive to finding mutants fitter than the wildtype in the presence of
antibiotics, enabling us to find many genes whose inactivation
increases antibiotic tolerance. Analysis of individual mutants
revealed a non-perfect correlation between a strain’s fitness
advantage in the conditions of the selection and its MIC in similar
conditions. Explanations for and implications of the variations are
discussed.
Results and Discussion
Selection of Transposon Insertion Mutants under Sub-
inhibitory Antibiotic Exposure
To characterize the contribution of all genetic loci to antibiotic
tolerance, we exposed a collection of mutants, each with a single
transposon insertion, to sub-inhibitory drug concentrations
(Figure 1). We chose 17 antibiotics that possess a range of
mechanisms of action (Table 1). These drugs inhibit various
cellular functions including the synthesis of proteins, nucleic acids,
folic acid, and cell wall [26,27]. As intermediate antibiotic
concentrations are typically the most selective for resistance [28],
during the selections, we used antibiotic concentrations that
impaired but did not completely inhibit the growth of the wild-
type strain (Table 1). Using a sensitive microarray-based strategy
[25], we then quantified the change in prevalence of different
transposon insertion mutants in parallel.
The final distribution was compared to both the original,
unselected library and to the library selected in the same media
without antibiotics (See Materials and Methods). Comparison to
populations grown in M9 media without antibiotics allowed media
and antibiotic effects to be distinguished. As some external stresses
such as low-level antibiotic exposure can ameliorate the deleteri-
ous nature of some mutations [29], the abundance of slow growing
mutants may increase in cultures with antibiotics compared to
cultures without antibiotics. Comparison to the unselected library
allowed the identification of insertion locations whose prevalence
had increased or decreased during the experiment and reduced
the chances of classifying slow-growing mutants as less susceptible.
Dataset S1 lists the loci whose disruption caused a significant
fitness change in each of the drugs tested. Heatmaps displaying the
data for loci whose disruptions were significant in individual drugs
and classes of drugs are in Figures S4–S11.
Validation of Global Fitness Profiling
Comparison to the literature indicates that we found many
genes whose removal is known to increase susceptibility (See
Tables S1–S4). However, attempts to set significance thresholds
that captured all such genes resulted in an unacceptable number of
false positives. As shown later in this work, some mutations confer
such a high degree of fitness in particular antibiotics that strains
possessing these mutations rapidly take over the population. The
existence of such highly fit mutants makes it difficult to distinguish
neutral transposon insertion locations from some with a slightly
deleterious effect because mutants with either are quickly lost from
the population. Consequently, when selecting genes for additional
study, an emphasis was placed on those whose removal increases
antibiotic tolerance.
To quantify the strength of the identified loci, we subjected the
wild-type parental strain to direct competition with mutant strains
in conditions that mimicked those of the selection (See Materials
and Methods and Text S1). The mutants tested behaved as
expected from the en mass library selections (Figure 2).
We also determined the MICs for a representative set of
individual mutants lacking genes judged to have a significant role
in antibiotic susceptibility. The relative efficiency of our MIC
measurement method (see Text S1) allowed us to analyze a larger
set of strains than would have been possible using only the more
labor-intensive direct competitions. As the initial selection process
did not require a change in MIC, the MICs provide complemen-
tary information about each mutation’s effect, and we did not
expect all beneficial (or deleterious) disruptions to cause an
increase (or decrease) in MIC. The most common result was a
change in MIC of 1.5 fold (the smallest change detectable with our
technique) in the expected direction—an increase (or decrease) for
a locus whose disruption was beneficial (or deleterious). We
observed increases up to ,5-fold and decreases down to ,7-fold
(Tables S5–S7).
Genes Exert Class-Specific Effects on Antibiotic
Susceptibility
Excluding the 30 genes identified as having general roles in
antibiotic susceptibility (see below), only antibiotics of the same
class have a substantial number of beneficial or deleterious
transposon insertion locations in common (Figure 3). Some
functional classes of antibiotics, particularly the b-lactams and
the aminoglycosides, have strong class-specific signatures, while
other classes, such as the quinolones, have few loci in common.
The number of loci impacting growth at the sub-inhibitory drug
concentrations tested varied greatly from the low hundreds for the
aminoglycosides down to zero for fusidic acid and erythromycin,
inhibitors of the 50S subunit of the ribosome to which E. coli is
intrinsically resistant [30]. The mutational target size observed
likely depends on both the antibiotic concentration assayed and
Antibiotic Fitness Landscape
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pathways may mask the contribution of some genes to antibiotic
tolerance.
The observation that disruptions caused increases in fitness
during drug exposure is characteristic of antagonistic pleiotropy
[31], which reflects an evolutionary tradeoff for increased drug
tolerance at the consequence of other traits. A large number of
disruptions fell into this category (336), suggesting that the
bacterium contains a large mutational target size for increasing
drug tolerance. To elucidate the pathways and mechanisms
contributing to susceptibility and tolerance, we analyzed the
identified loci for three drug classes – the aminoglycosides
(Figure 4), the b-lactams (Figure 5), and the folic acid biosynthesis
inhibitors (Figure 6) – in more detail. In each case, the data
indicate the major pathways involved and the many ways that
mutations can modulate those pathways.
Mutations Beneficial in the Presence of Aminoglycosides
Excluding loci with a general effect on antibiotic tolerance,
disruptions of 73 loci were beneficial in all four aminoglycosides
tested while disruptions of 14 loci were deleterious (Figure 4A).
Using an aerobic environment – a condition where many
antibiotics, especially aminoglycosides, are particularly effective
[32] – likely increased the number and types of beneficial
mutations identified. The set of beneficial disruption loci is
enriched for genes with products involved in quinone binding
(p=1.7610
215), ubiquinone biosynthesis (p=1.1610
25), glycoly-
sis (p=1.5610
27), L-serine biosynthesis (p=1.2610
23), and
cytochrome-c oxidase activity (p=1.2610
23). Additionally, the
set is enriched for genes down-regulated in response to oxygen
depravation (p=3.5610
216). Forty-eight of the beneficial muta-
tions likely reduce the number of harmful hydroxyl radicals
created by the Fenton reaction, part of a death-inducing chain
reaction triggered by bactericidal antibiotics that includes NADH
depletion, superoxide generation, and iron-sulfur center destabi-
lization [33] (Figure 4B). Kohanski et al. [34] found that a set of E.
coli strains with similar mutations had increased growth in the
presence of gentamycin. Similarly, Schurek et al. [22] found that
mutants of Pseudomonas aeruginosa with disruptions in homologous
genes had increased tobramycin resistance
To understand the magnitude of the tolerance changes, we
competed a nuoG::kan strain with the wild-type strain. While the
nuoG::kan strain was at a slight disadvantage in the media without
drugs, in the presence of amikacin, the mutant rapidly took over
the culture (Figure 2). In contrast, the nuoG::kan strain and other
mutants that perturbed the pathway leading to death from Fenton
reaction-derived hydroxyl radicals had at most modest (less than 3-
fold) increases in MICs and frequently failed to exhibit any
Figure 1. Overview of experimental protocol. (A) An aliquot of a library containing ,5610
5 mutants each with a single transposon insertion
[25] was taken from frozen stock, grown overnight in LB, pelleted, washed, and resuspended at 2% inoculum in fresh M9-media containing an
antibiotic at the chosen concentration (Table 1). Each day, an aliquot was frozen, and 2% of the culture was transferred to fresh media to continue the
selection. Genetic footprinting was performed on frozen samples to amplify the region of genomic DNA adjacent to the transposon in each of the
mutants [25]. DNA was subsequently labeled and hybridized with a reference of labeled genomic DNA to spotted microarrays [25]. (B) Dose response
curves were used to select drug concentrations. For each antibiotic, fresh media containing various drug concentrations was inoculated with
overnight culture of the wild-type strain. Growth was monitored using OD600 readings. Shown are the curves for amikacin; curves for all other
antibiotics are in Figure S1. Typically, we selected moderately inhibitory drug concentrations that reduced the growth after 14 hours by 30–50%. (C)
Separation of DNA on an agarose gel provided a qualitative depiction of the population diversity after each day of selection. Shown are the amplified
Tn-adjacent DNA from all seven days of one of the ampicillin selections. Selections performed without antibiotic showed no discernable banding
pattern (Figure S2). Gel images for all selections with antibiotics are in Figure S3.
doi:10.1371/journal.pone.0005629.g001
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Name Code
Dose
(mg/ ml) Day # Samples Class Cellular Target
Bactericidal or
Bacteriostatic
Ampicillin AMP 3 2 3 b-lactam Cell wall biosynthesis Bactericidal
Amikacin AMK 1 4 2 Aminoglycoside Protein synthesis, 30S Bactericidal
Bleomycin BLM 1 2 2 Peptide Nucleic acid Bacteriostatic
Cefoxitin FOX 1 3 2 b-lactam Cell wall biosynthesis Bactericidal
Doxycycline hyclate DOX 0.5 2/3* 3 Tetracycline Protein synthesis, 30S Bacteriostatic
Erythromycin ERY 2 3 2 Macrolide Protein synthesis, 50S Bacteriostatic
Fusidic acid FUS 180 4 2 Protein synthesis, 50S Bacteriostatic
Gentamycin GEN 0.1 2 2 Aminoglycoside Protein synthesis, 30S Bactericidal
Lomefloxacin LOM 0.05 2/3* 3 Quinolone DNA gyrase Bactericidal
Nalidixic acid NAL 4 2 2 Quinolone DNA gyrase Bactericidal
Nitrofurantoin NIT 4 3 2 Nitroheterocyclic Multiple Targets Bactericidal
Piperacillin PIP 1 4 2 b-lactam Cell wall biosynthesis Bactericidal
Streptomycin STR 3 2 3 Aminoglycoside Protein synthesis, 30 S Bactericidal
Sulfamonomethoxine SLF 0.5 2/3* 2 Sulfonamide Folic acid biosynthesis Bacteriostatic
Tetracycline TET 0.25 2 2 Tetracycline Protein synthesis, 30S Bacteriostatic
Tobramycin TOB 0.25 2 2 Aminoglycoside Protein synthesis, 30S Bactericidal
Trimethoprim TRM 0.5 4 2 DHFR Inhibitor Folic acid biosynthesis Bacteriostatic
*Two samples from day 2 and one from day 3 were hybridized and analyzed.
doi:10.1371/journal.pone.0005629.t001
Figure 2. Selection rates during direct competitions. Selection rates (generations/day) were calculated as (log2(A(t1)/A(t0))2log2(B(t1)/B(t0)))/
(t12t0) [87]. A(t0) and B(t0) are, respectively, the mutant and the wild-type population sizes at t0, the beginning of the competition, and A(t1) and B(t1)
are the mutant and the wild-type population sizes at t1, the end of the competition. Shown are the average and standard deviation of three
repetitions. The selection rate for the trpA::kan mutant in amikacin was calculated after two days of enrichment to correspond with the samples
hybridized. The trpA::kan strain’s reliance on tryptophan from lysed wild-type cells prevents the mutant from taking over the culture, and during
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are more active in the shaken cultures used for the competitions
than in static MIC-measurement plates, the fitness effect of
removing genes that contribute to the Fenton pathway likely
depends strongly on the oxygen level.
Disruptions expected to interfere with the death pathway
mediated by the Fenton reaction were widely beneficial only in
selections with aminoglycosides, even though all bactericidal
antibiotics are thought to trigger the pathway [33]. Furthermore,
since the selections were performed at antibiotic concentrations
that reduced, but did not completely inhibit, the wild-type strain’s
growth, observing genetic interactions with a putative death
process was initially puzzling.
An explanation for the apparent paradox came from the
observation that during the enrichments in amikacin and
streptomycin, disruptions in tryptophan biosynthesis genes that
should have been lethal in the growth media, which lacked
tryptophan, were strongly beneficial. We confirmed that a trpA::kan
mutant does not grow in the media, with or without antibiotics,
and that when trpA::kan and wild-type strains compete without
antibiotics, the wild-type strain rapidly takes over (Figure 2). When
trpA::kan and wild-type strains compete in the presence of
amikacin, however, the trpA::kan strain remains an appreciable
part of the population (Figure 2). Presumably, a portion of the
wild-type cells are dying, lysing, and releasing enough tryptophan
to support the trpA::kan mutant. Thus, in the aminoglycoside
enrichments, although the overall population was growing,
individual cells were dying. The existence of similar concentration
regimes for other bactericidal drugs remains an interesting area for
future inquiry.
Several beneficial disruptions that likely reduce NADH
accumulation and lower the metabolic flux through the Fenton
reaction may also provide secondary benefits. First, disruption of
electron transport reduces the uptake of aminoglycosides [35].
Second, mutations that keep cAMP-CRP (cyclic AMP bound to
the CRP transcription factor) levels low reduce the transcription of
Figure 3. Overlap between genes influencing fitness in partially inhibitory concentrations of different antibiotics. Squares on the
main diagonals indicate the number of genes whose disruption caused a significant fitness effect (See Materials and Methods). Genes causing general
changes in antibiotic susceptibility (Figure 7) were excluded. The lower left (upper right) triangle reports on genes whose disruption was beneficial
(deleterious) to E. coli in the presence of the indicated antibiotic. Off-diagonal squares indicate how many genes caused significant fitness changes in
both antibiotics when disrupted. The shading shows the likelihood of an overlap of the indicated size or larger occurring by chance and was
calculated using the hypergeometric distribution. P-values were corrected for multiple testing. Erythromycin and fusidic acid are not shown as the
only genes whose disruption affected fitness caused general changes in susceptibility.
doi:10.1371/journal.pone.0005629.g003
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transporters with affinity for aminoglycosides [36]. Disruptions of
both cyaA, which encodes adenylate cyclase, and crp were
beneficial during the aminoglycoside selections, and a cyaA::kan
mutant has a higher MIC than the wildtype in three of the four
aminoglycosides tested (Table S5). (crp does not appear in Figure 4
due to lack of data in gentamycin and tobramycin; cyaA is not in
Figure 4 because its deletion was generally advantageous.)
Transposon insertions in ptsH, ptsI, and crr, which are expected
to lower cAMP levels [37], were also advantageous. Additionally,
synthesis of the large cAMP-CRP regulon, which is expected to
occur when the glucose in the media is exhausted [38], may not be
the optimal allocation of cellular resources during antibiotic
challenge. Salmonella strains lacking either cyaA or crp are more
resistant to a wide range of antibiotics [39], suggesting that similar
phenomena may occur with other organisms and antibiotics.
Other beneficial disruptions seem to alter the timing and
magnitude of the stringent response, a program E. coli uses to
redirect energy from rRNA and tRNA transcription to the
creation of amino acid biosynthesis enzymes in response to amino
acid starvation [40]. To accomplish the transition, Lon protease
bound to polyphosphate degrades ribosomal proteins, freeing
amino acids that can be incorporated into the needed enzymes
[41], and guanosine tetraphosphate (ppGpp) and guanosine
pentaphosphate (pppGpp) bind RNA polymerase, altering pro-
moter selectivity [42]. Transposon insertions near gpp or spoT,
genes whose products affect the levels and ratio of ppGpp and
pppGpp [43], are beneficial in aminoglycosides (Figure 4 and
Table S5). Similarly, insertions near ppk, which encodes polypho-
sphate kinase [44], or lon are beneficial in tetracyclines (Table S6).
The advantageous character of cpxA and cpxP disruptions points
to a role for the Cpx system, which helps E. coli respond to
extracytoplasmic stress [45], in aminoglycoside susceptibility. At
the core of the Cpx system are the CpxA histidine kinase, its
cognate response regulator, CpxR, and CpxP, a periplasmic
repressor of CpxA [45]. Recent work indicates that the presence of
the wild-type Cpx system increases the number of hydroxyl
radicals, the final output of the Fenton reaction death pathway,
possibly through crosstalk with the Arc system [34]. Somewhat
surprisingly, however, in the absence of CpxA, the cellular pool of
Figure 4. Disruption of electron transport and oxidative respiration reduces susceptibility to aminoglycosides. (A) The heatmaps, in
which hierarchical clustering was used to order both the genes and the drugs [84], show loci whose disruption changed susceptibility to all four
aminoglycosides tested (See Materials and Methods). Table S1 lists the genes with annotations. (B) Of the 73 transposon insertions regions identified
as beneficial in all four aminoglycosides, the 48 shown are expected to reduce Fenton reaction-based oxidative damage. Following exposure to lethal
concentrations of bactericidal antibiotics, the oxidative electron transport chain depletes the NADH pool, generating high levels of superoxide, which
removes iron from iron-sulfur clusters [33]. The free iron subsequently generates hydroxyl radicals through the Fenton reaction [33]. Removal of key
catabolic enzymes should shrink the NADH pool and reduce the flux through the electron transport chain. The media used lacks cysteine, the sulfur
donor for iron-sulfur center synthesis [88], so disruption of cysteine biosynthesis should reduce the availability of sulfur for iron-sulfur centers. The
iron-sulfur center synthesis genes shown are not specific for NADH dehydrogenase I, and their disruption should reduce the number of iron-sulfur
clusters throughout the cell. Q: ubiquinone; FMN: flavin mononucleotide; FAD: flavin adenine dinucleotide
doi:10.1371/journal.pone.0005629.g004
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not off [46]. Furthermore, some mutations that constitutively
activate the Cpx system cause pleiotrophic effects including
amikacin [47] and kanamycin resistance [48], possibly through
the increased expression of drug efflux pumps [49]. Different levels
of Cpx-Arc crosstalk between the various mutant and wild-type
strains may account for these observations.
Mutations Affecting Susceptibility to b-lactams
Excluding loci with a general effect on antibiotic tolerance,
disruption of 33 loci was beneficial in all three b-lactams tested,
while disruption of 12 loci was deleterious (Figure 5A). Many of
the beneficial disruptions turn on the Rcs signaling pathway
(Figure 5B), which Laubacher and Ades [50] previously found to
contribute to b-lactam tolerance. Laubacher and Ades also
showed that the tolerance is not dependent on the Rcs system’s
role in increasing capsule synthesis [50]; they did not, however,
evaluate the importance of the system’s function in suppressing
flagella-based motility [51]. Since many other disruptions
beneficial in b-lactams are in genes whose products participate
in flagella assembly, we hypothesize that suppression of flagella
synthesis is responsible for the beneficial effect of Rcs system
activation.
To confirm that the lack of flagella confers an advantage in b-
lactams, we focused on a fliN::kan mutant in the presence of
ampicillin. In direct competition with the parental strain, the
mutant has a small advantage in media without drug, likely due to
the high energetic cost of motility [52] (Figure 2). With ampicillin,
however, the advantage is much larger (Figure 2), possibly because
energy is a more valuable commodity in antibiotic-stressed cells.
Alternatively, since assembling a flagellum requires peptidoglycan
Figure 5. Reduced flagella synthesis is advantageous in b-lactams. (A) The heatmaps shows loci whose disruption changed susceptibility to
all three b-lactams tested (See Materials and Methods). Hierarchical clustering was used to order both genes and drugs [84]. Table S2 lists the genes
with annotations. (B) Both transposon insertions that disrupt genes that encode flagella components as well as insertions that indirectly reduce
flagella synthesis by activating the Rcs system are beneficial. The core components of the Rcs system are RcsC, a hybrid sensor kinase, RcsD, a
histidine phosphotransferase, and RcsB, a DNA-binding response regulator [89]. Other components are RcsF, a lipoprotein that activates RcsC [90,91],
and RcsA, a transcription factor that forms a heterodimer with RcsB [92]. Together, RcsA and RcsB repress transcription of flhDC, the master regulator
of flagella synthesis [51]. RcsA is a target of the Lon protease [93], and insertions in lon, which stabilize RcsA, are beneficial. RcsC and RcsD both
transfer phosphate to as well as remove phosphate from RcsB, resulting in higher activation of the Rcs system in rcsC or rcsD mutants than in
wildtype [90,94]. Insertions in mdoG and mdoH, which encode proteins that synthesize osmoregulated periplasmic glucans (OPGs), reduce motility by
activating the Rcs system [25]. The beneficial effects of mdoG, modH, and rcsC disruptions are not limited to b-lactams (Figure 7).
doi:10.1371/journal.pone.0005629.g005
Figure 6. Genetic and chemical perturbations of the folate
biosynthesis pathway. Sulfamonomethoxine inhibits FolP, a dihy-
dropteroate synthase [95]; trimethoprim inhibits FolA, the cell’s main
dihydrofolate reductase (DHFR) [56]. FolM, which also acts as a DHFR, is
not inhibited by trimethoprim [58]. Mutants lacking folM or folX are less
sensitive to both to trimethoprim and sulfamonomethoxine.
doi:10.1371/journal.pone.0005629.g006
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tion, the combination of stresses may interact synergistically.
Interestingly, the MIC of the filN::kan mutant as well as that of
several other strains with increased fitness in ampicillin is within
measurement error of that of the wild-type strain (data not shown),
highlighting the ability of the selection method employed to
identify mutations of small effect.
Disruptions expected to work synergistically with b-lactams to
disrupt peptidoglycan integrity are particularly harmful
(Figure 5A). For example, loss of either mltB or slt, which encode
membrane-bound lytic murein transglycosylases [54], is deleteri-
ous. Disruptions of ampG, which encodes a transporter involved in
recycling murein [55], or of ampC, which encodes a b-lactamase
resistance protein [55], are also detrimental.
Disruption of folX or folM is Beneficial in Drugs that
Inhibit Folate Biosynthesis
The only locus whose disruption was beneficial in both
sulfamonomethoxine and trimethoprim, two drugs that inhibit
key steps in folate metabolism (Figure 6), was folM, which encodes
one of E. coli’s two dihydrofolate reductases (DHFRs). E. coli’s
other DHFR, FolA, is inhibited by trimethoprim [56], and folA is
essential in minimal media unless thyA is also knocked out and the
media is supplemented with thymidine [57]. In contrast, folM
deletion strains have no major growth defects, and trimethoprim
does not inhibit FolM [58]. A folM::kan mutant has a 5-fold higher
MIC in sulfamonomethoxine than the wild-type strain, but no
detectable change in MIC in trimethoprim (Table S2). To assess
the strain’s fitness more sensitively, we subjected the folM::kan
strain to direct competition with the wild-type strain and found
that the folM::kan mutation is neutral without drug and beneficial
in the presence of trimethoprim (Figure 2). That the effects in
sulfamonomethoxine are stronger than those in trimethoprim is
consistent with the original transposon enrichment experiments,
which needed two and four days to find loci affecting susceptibility
to sulfamonomethoxine and trimethoprim, respectively. The
beneficial nature of folM deletions in sulfamonomethoxine and
trimethoprim is surprising, as deleting folM would naively be
expected to reduce the available amount of DHFR, making a bad
situation worse. We hypothesize that E. coli may respond to a lack
of FolM by increasing FolA levels, ameliorating the effects of
sulfamonomethoxine and trimethoprim.
Another gene connected to folate biosynthesis whose disruption
was beneficial during the trimethoprim enrichment is folX.
Although the folX data slightly missed the significance thresholds
for the sulfamonomethoxine enrichment, deleting folX gave a ,2-
fold increase in MIC in sulfamonomethoxine (Table S2). Like
folM,afolX deletion did not change the MIC in trimethoprim, but
the mutant strain did have a competitive advantage over the wild-
type strain in trimethoprim (Figure 2). FolX catalyzes the
conversion of 7,8-dihydroneopterin triphosphate to dihydromo-
napterin-triphosphate [59], which redirects 7,8-dihydroneopterin
triphosphate away from the synthesis of tetrahydrofolate (Figure 6).
Thus, folX mutations likely allow metabolic compensation [60] by
increasing the flux of metabolites through the folate biosynthesis
pathway. In fact, increased flux from enhanced p-aminobenzoate
production is a common mechanism of sulfamonomethoxine
resistance [61].
Loci Conferring a General Increase or Decrease in
Antibiotic Susceptibility
Transposon insertions in or near 30 genes provided a significant
change in fitness in at least three antibiotics with distinct targets
(Figure 7). While some drugs of the same class, such as the
aminoglycosides have similar fitness profiles, a mutant’s behavior
in the presence of a drug cannot generally be determined based
solely on knowledge of the drug’s mechanism of action. This is
especially true for drugs of the same class, such as tetracycline and
doxycycline, which have distinct chemical properties that restrict
them to different routes of entry into the cell. In particular, the
comparatively hydrophilic tetracycline passes through OmpF
porins while the more hydrophobic doxycycline diffuses through
the outer membrane [62].
E. coli generates multiple barriers to protect itself from different
classes of harmful, foreign compounds, and we found, as expected,
Figure 7. Genes altering susceptibility to three or more classes
of antibiotics. Yellow (blue) indicates that transposon insertions in or
near a gene were beneficial (deleterious). Black indicates no significant
effect; gray indicates missing data. Antibiotics with the same target are
written in the same color. Sulfamonomethoxine and trimethoprim
inhibit different enzymes in the folic acid biosynthesis pathway; placing
them in separate classes did not alter the results. Z-scores were
calculated as described in Materials and Methods.
doi:10.1371/journal.pone.0005629.g007
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susceptibility encode enzymes that synthesize cell envelope
components. In particular, perturbations to the negatively-charged
lipopolysaccharides (LPS) and enterobacteria common antigen
(ECA) that protect the outer membrane [63,64] were widely
deleterious. Defective LPS is known to increase sensitivity to
hydrophobic antibiotics and polycationic compounds such as
aminoglycosides [63]. ECA, on the other hand, is thought to
provide protection against organic acids [65], but its role in
antibiotic tolerance had not been well explored; Tamae et al. [20]
did, however, report that loss of rffA increases susceptibility to
gentamycin. Strains with defective ECA (i.e., wzxE::kan) and LPS
(i.e., rfaG::kan) generally had lower MICs than wild-type in the
same antibiotics in which they were depleted during the selections
(Table S7). Direct competitions with a wild-type strain confirmed
that a DwzxE mutation is neutral in media without drug and
deleterious in both nalidixic acid and amikacin (Figure 2).
Rarely was the disruption of a locus beneficial in the presence of
some drugs and deleterious in others. Notable exceptions are yrbB
and yrbE, whose products belong to a system that prevents
mislocalized phospholipids from accumulating in the outer
membrane’s outer leaflet [66]. We confirmed that a yrbE::kan strain
has a higher MIC than the wildtype in bleomycin, has similar
tolerance to the wildtype in tetracycline, and is more susceptible
than the wildtype to nalidixic acid, lomefloxacin, and doxycycline
(Table S7). Loss of the Yrb system likely has little effect in
tetracycline because tetracycline enters the cell using porins rather
than passing directly through the outer membrane [62]. Defects in
the Yrb system likely reduce the negative charge on the outer
membrane, which would decrease the permeability to positively
charged bleomycin and increase the permeability towards the more
neutral and negatively charged nalidixic acid, lomefloxacin, and
doxycycline. The mechanism may be similar to how expression of
the PmrA regulon, which makes the LPS less negative, increases E.
coli’s tolerance to the positively charged polymyxin B but also
increases susceptibility to anionic detergents [67].
To increase antibiotic tolerance, bacteria often reduce the
intracellular drug concentration by increasing the expression of
efflux pumps that use either ATP or membrane potential to expel
toxic agents [68]. Not surprisingly, disruption of genes that control
the levels of the AcrB/AcrA/TolC system, E. coli’s main drug
efflux pump [69], alters tolerance to multiple antibiotics.
Disruption of the acrB gene is widely deleterious (Figure 7).
Disruptions of phoP or rob, which encode transcriptional activators
of the acrAB operon [70,71], are also deleterious, while disruption
of acrR, which encodes a transcriptional repressor of the acrAB
operon [72], is beneficial. Disruption of no other drug pump was
generally deleterious.
Disruption of E. coli’s Trk potassium transport system was
beneficial in a wide range of antibiotics. The low-affinity
transporter contains TrkA, TrkE (SapD), and either TrkH or
TrkG proteins [73,74], and the Tn-enrichment experiment
indicated that disruptions in sapD, trkA, and trkH are beneficial
in piperacillin, doxycycline, tetracycline, and nalidixic acid
(Figure 7). Work with a sapD::kan mutant indicated that removal
of the system increases the MIC by about 1.5-fold in doxycycline,
tetracycline, and nalidixic acid (Table S7). In direct competitions
between a DsapD mutant and the parental strain, the DsapD
mutation was slightly deleterious in the absence of drug, beneficial
in the presence of nalidixic acid, and neutral with tetracycline
(Figure 2). The connection between potassium transport and
antibiotic tolerance merits further study.
Notably, disruptions of two genes of unknown function, yecR
and yfgC, are deleterious (Figure 7). Tamae et al. [20] found that
removal of yfgC decreases the MIC in vancomycin, rifampicin, and
ampicillin. We confirmed the result for ampicillin, and we found
that the MIC is also lower than wild-type in fusidic acid,
doxycycline, and trimethoprim (Table S7). yfgC has homology to
peptidases, and PSORTb [75] predicts that the protein is in the
inner membrane. yecR is regulated by FlhDC [76] and has
homology to lipoproteins. Strong homologs to yecR are found only
in other Enterobacter species; homologs for yfgC are slightly more
widespread, appearing in multiple gamma-proteobacteria.
Resistance through Accumulation of Mutations of Small
Effect
To explore the potential for E. coli to acquire higher levels of
antibiotic tolerance through the sequential accumulation of the
identified chromosomal mutations, we constructed several double
mutants. For each of two drugs, from among the genes that gave
measurable MIC increases when removed singly, we chose pairs
that were putatively in different pathways. As expected, the double
mutants exhibited higher MICs than the parental strain and both
of the two single mutant derivatives. In particular, ybjC::kan and
ompR::kan mutants have MICs 2.25-fold greater than the wild-type
strain in nitrofurantoin, while a DompR ybjC::kan double mutant has
a MIC 5-fold greater than the wild-type strain. The ybjC::kan
allele’s beneficial effects likely come from reduced expression of
the downstream nfsA gene, which encodes an oxygen-insensitive
nitroreductase that converts nitrofurantoin into toxic intermediates
[77]. Similarly, MICs of sapD::kan and lon::kan mutants in
tetracycline are 1.5-fold higher than the wild-type strain, and the
MIC of a DsapD lon::kan mutant is 2.25-fold greater than the wild-
type parent.
A wide variety of mutations, including single base pair changes,
can cause the null phenotypes attained in this work through
transposon insertions and gene replacements. Furthermore, for
most antibiotics, the set of beneficial disruptions spans multiple
pathways. Thus, E. coli’s current genome is likely mutationally close
to one conferring significantly higher antibiotic tolerance. A clinical
S. aureus strain was observed acquiring 35 chromosomal mutations
on the way to vancomycin resistance [78], and in the laboratory,
multiple weak chromosomal mutations have been combined to give
higher resistance in both P. aeruginosa [24] and Helicobacter pylori [23],
suggesting that the phenomenon is quite general.
Concluding Remarks
In this work, we competitively grew transposon insertion
mutants of E. coli in batch cultures with drug concentrations that
had a moderate impact on the parental strain’s growth rate.
Propagating the mutant collection for a sufficiently long duration
allowed us to identify both beneficial and deleterious mutations of
a wide range of strengths. Our analyses reveal that E. coli has a
large mutational target size for altering its antibiotic tolerance.
As the disruption of the genes identified in this study pushes cells
from the growth regime of moderate inhibition towards one of the
extremes of no inhibition or full inhibition, the products of the loci
and the pathways in which they reside are promising starting
points for the development of adjuvant therapies. For example, if a
gene’s deletion causes hypersensitivity to an antibiotic, that
antibiotic and a drug targeting the corresponding gene product
may act synergistically. Similarly, when disrupting a pathway
increases bacterial fitness in the presence of a particular antibiotic,
stimulating the pathway might enhance the antibiotic’s efficacy.
The development of such adjuvant therapies has the potential to
expand the usefulness of the limited set of antibiotics currently
available.
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able, this work should provide a wealth of data for interpreting
mutations present in drug resistant, pathogenic strains. As
approximately half of the genes identified as altering fitness in
the presence of antibiotics increase tolerance when disrupted, it
will be important to learn how frequently and in what
combinations the adaptive building blocks revealed here appear
in clinical and environmental settings. The bulk of the loci
identified occur in multiple species, and future work will be needed
to discover how specific the beneficial and deleterious nature of
each perturbation is to the wiring of E. coli’s cellular network. Our
observations should provide a scaffold for understanding the
contribution of chromosomal mutations to antibiotic resistance as
well as an aid in the development of novel therapeutics.
Materials and Methods
Bacterial Strains and Growth Conditions
All experiments were performed using E. coli MG1655 [79].
Transposon insertion mutants were generated in a MG1655 DlacZ
strain as described in a previous study [25]. All experiments were
conducted in M9 salts [80] supplemented with 0.4% glucose, 0.1%
casamino acids, 1 mM MgSO4, 0.1 mM CaCl2, and 1.5 mM
thiamine. LB media contained 0.1% Bacto Tryptone, 0.05% yeast
extract, and 0.05% NaCl. All antibiotics were purchased from
Sigma. Unless otherwise noted, cultures were shaken at 37uC.
Transposon Library Enrichments, DNA manipulation, and
Hybridization
Genetic footprinting and subsequent hybridization to DNA
spotted arrays were performed as described in Girgis et al. [25]. As
a starting point, we hybridized DNA from the day in which minor
banding patterns began to emerge (Figure 1C) and then adjusted
the chosen day as necessary. On early days during a selection, a
mutant’s fitness did not have a measurable effect on its prevalence,
while on very late days, only a few types of mutants remained, and
the relative fitness of the mutants that completely dropped out
could not be discerned. In a few cases (Table 1), data from
adjacent days of roughly equal suitability were included in the
analysis. Other hybridizations from days not ultimately chosen
exhibited either extreme selection or little to no selection and were
excluded. The distinct behavior of the library in each antibiotic
necessitated the choice of different days for different antibiotics
(Table 1). To reduce the chance of spontaneous mutations
overtaking the cultures, to remove the need for additional sets of
controls for comparison, and to focus on transposon insertions
causing larger effects, no samples from days 5–7 were chosen.
Samples from at least two independent replicate selections were
hybridized for each antibiotic. As controls, six samples from
independent selections in the absence of any drug were hybridized.
Determining Significant Changes
Ratios (transposon signal/genomic DNA signal) from the
antibiotic enrichments were compared to both the ratios from
the original unselected library and to ratios from enrichments of
the transposon library performed in identical media without
antibiotics. Two z-scores were calculated for each ratio, r, where
z=(x2m)/s, x=log2(r), and m and s are the mean and standard
deviation, respectively, of the log2 ratios for the gene from
reference hybridizations. One z-score used five reference hybrid-
izations of the unselected library (from Girgis et al. [25]) and the
other used six reference hybridizations of the library selected in the
same media without antibiotics. All six no-antibiotic samples came
from independent selections; three selections lasted two days, and
three lasted four days.
To identify the mostreproducible fitness effects, we consideredall
of the z-scores for each gene for a given antibiotic. (Antibiotics with
two and three hybridizations had four and six z-scores, respectively.)
When all of the z-scores had the same sign, we assigned the gene the
z-score in the set that was closest to zero (representing the smallest
effect). When a gene had z-scores of different signs, the gene was
assigned a score of 0, indicating no consistent fitness effect.
Supplementary information contains normalized ratios (Dataset
S2), z-scores relative to the unselected library (Dataset S3), z-scores
relative to the enrichments performed in the media without
antibiotics (Dataset S4), combined z-scores (Dataset S5), and the
combined z-scores considered significant (Dataset S1).
The significance threshold was set so that two false positives are
expected per antibiotic. False positives were estimated by treating
randomly chosen reference samples as data and repeating the
analysis procedure. (See Text S1.)
Determining Genes Common to Aminoglycosides and b-
lactams
In identifying loci important to fitness in specific antibiotic
classes, care was taken to prevent the exclusion of genes that barely
missed the significance cutoff for a subset of the drugs. As such, a
locus was considered to be beneficial or deleterious in aminogly-
cosides if i) the prevalence of mutants where the locus was
disrupted changed significantly during the enrichments for at least
two of the four drugs and ii) the z-scores for the locus for all four
drugs had the same sign. For example, disruption of a locus was
classified as beneficial in aminoglycosides if the gene had positive
z-scores in all four drugs, and the z-scores reached the significance
level for at least two drugs. b-lactams were treated similarly except
that the disruption of a locus was required to cause a significant
fitness change during the enrichments for at least one of three
drugs. Loci with a general effect on antibiotic tolerance were
excluded from the sets.
Strain Construction
Ratherthan choosingoneofthemanymutants inthe librarywith
a transposon inserted in a particular gene, we corroborated
behavior observed during the selections using strains where the
gene of interest had either been replaced with a kanamycin (kan)
resistance cassette or removed to create an in-frame deletion. To
construct the strains, P1vir transduction [81] was used to move the
necessary alleles from the Keio collection [82] to MG1655 [79]. To
create unmarked, in-frame deletions, the kan cassette was removed
using FLP recombinase [83]. In rare cases, both the original
transposon insertions as well as the kanamycin resistance cassette
can produce polar effects, resulting in mutants with phenotypes
distinct from the null phenotype of the disrupted or replaced gene.
Software Used
Data was clustered with Cluster [84] and visualized using
Treeview [84]. Data manipulations were performed using Perl and
Matlab. iPAGE (Hani Goodarzi, unpublished data) was used to
examine sets of genes for enrichments in GO category,
transcription factor regulon, and stress response membership.
Annotations came from EcoCyc [85] and genome-tools [86].
Supporting Information
Text S1 Additional Materials and Methods
Found at: doi:10.1371/journal.pone.0005629.s001 (0.07 MB
PDF)
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Concentrations. For each antibiotic, fresh media containing
various drug concentrations was inoculated with overnight culture
of the wild-type strain. Cultures were shaken at 37uC, and growth
was monitored using OD600 readings. Blue indicates the
concentrations chosen for the enrichments.
Found at: doi:10.1371/journal.pone.0005629.s002 (0.18 MB
PDF)
Figure S2 Gel images from enrichments done in the study
media in the absence of antibiotics. Shown are the amplified Tn-
adjacent DNA from all seven days for each of the seven
repetitions. DNA was amplified as described in Girgis et al. [1]
and separated on a 2% agarose gel. Yellow rectangles indicate
samples hybridized. From the bottom, marker sizes are 100, 200,
300, 400, 500, 650, 850, and 1000 bases.
Found at: doi:10.1371/journal.pone.0005629.s003 (1.48 MB
PDF)
Figure S3 Gel images from Tn-insertion library enrichments
done in the presence of antibiotics. Shown are the amplified Tn-
adjacent DNA from all seven days for each of the three repetitions
done for each antibiotic. DNA was amplified as described in Girgis
et al. [1] and separated on a 2% agarose gel. Yellow rectangles
indicate samples hybridized. From the bottom, marker sizes are
100, 200, 300, 400, 500, 650, 850, and 1000 bases.
Found at: doi:10.1371/journal.pone.0005629.s004 (2.10 MB
PDF)
Figure S4 Loci whose disruption was significant in at least one
quinolone. Yellow (blue) indicates that transposon insertions in or
near a gene were beneficial (deleterious). Black indicates no
significant effect. Z-scores were calculated as described in
Materials and Methods.
Found at: doi:10.1371/journal.pone.0005629.s005 (0.21 MB
PDF)
Figure S5 Loci whose disruption was significant in at least one
tetracycline. Yellow (blue) indicates that transposon insertions in or
near a gene were beneficial (deleterious). Black indicates no
significant effect; gray indicates missing data. Z-scores were
calculated as described in Materials and Methods.
Found at: doi:10.1371/journal.pone.0005629.s006 (0.24 MB
PDF)
Figure S6 Loci whose disruption was significant in at least one
folic acid biosynthesis inhibitor. Yellow (blue) indicates that
transposon insertions in or near a gene were beneficial
(deleterious). Black indicates no significant effect; gray indicates
missing data. Z-scores were calculated as described in Materials
and Methods.
Found at: doi:10.1371/journal.pone.0005629.s007 (0.13 MB
PDF)
Figure S7 Loci whose disruption was significant in at least one
inhibitor of the 50S subunit of the ribosome. Yellow (blue)
indicates that transposon insertions in or near a gene were
beneficial (deleterious). Black indicates no significant effect. Z-
scores were calculated as described in Materials and Methods.
Found at: doi:10.1371/journal.pone.0005629.s008 (0.08 MB
PDF)
Figure S8 Loci whose disruption was significant in bleomycin.
Yellow (blue) indicates that transposon insertions in or near a gene
were beneficial (deleterious). Z-scores were calculated as described
in Materials and Methods.
Found at: doi:10.1371/journal.pone.0005629.s009 (0.13 MB
PDF)
Figure S9 Loci whose disruption was significant in at least one
b-lactam. Yellow (blue) indicates that transposon insertions in or
near a gene were beneficial (deleterious). Black indicates no
significant effect. Z-scores were calculated as described in
Materials and Methods. Note that this set of loci is distinct from
the set of loci whose disruption caused significant changes in all the
beta-lactams tested (Table S2).
Found at: doi:10.1371/journal.pone.0005629.s010 (0.10 MB
PDF)
Figure S10 Loci whose disruption was significant in nitrofuran-
toin. Yellow (blue) indicates that transposon insertions in or near a
gene were beneficial (deleterious). Z-scores were calculated as
described in Methods.
Found at: doi:10.1371/journal.pone.0005629.s011 (0.09 MB
PDF)
Figure S11 Loci whose disruption was significant in at least one
aminoglycoside. Due to the large size of the set, genes whose
disruption was only significant in tobramycin are not shown. Data
for tobramycin is available in Dataset S1. Yellow (blue) indicates
that transposon insertions in or near a gene were beneficial
(deleterious). Black indicates no significant effect; gray indicates
missing data.
Found at: doi:10.1371/journal.pone.0005629.s012 (0.24 MB
PDF)
Table S1 Loci that changed susceptibility to all aminoglycosides
tested.
Found at: doi:10.1371/journal.pone.0005629.s013 (0.08 MB
PDF)
Table S2 Loci that changed susceptibility to all beta-lactams
tested.
Found at: doi:10.1371/journal.pone.0005629.s014 (0.07 MB
PDF)
Table S3 Genes identified in this work as having a general role
in antibiotic susceptibility.
Found at: doi:10.1371/journal.pone.0005629.s015 (0.07 MB
PDF)
Table S4 Additional genes identified in both this study and
previous work.
Found at: doi:10.1371/journal.pone.0005629.s016 (0.07 MB
PDF)
Table S5 MIC changes in aminoglycosides.
Found at: doi:10.1371/journal.pone.0005629.s017 (0.06 MB
PDF)
Table S6 Additional class-specific MIC changes (non-aminogly-
cosides).
Found at: doi:10.1371/journal.pone.0005629.s018 (0.07 MB
PDF)
Table S7 MIC changes for mutants with altered susceptibility to
multiple drug classes.
Found at: doi:10.1371/journal.pone.0005629.s019 (0.07 MB
PDF)
Dataset S1 Z-scores for loci with a significant effect on antibiotic
susceptibility.
Found at: doi:10.1371/journal.pone.0005629.s020 (0.90 MB
XLS)
Dataset S2 Normalized ratios (transposon signal/genomic DNA
signal)
Found at: doi:10.1371/journal.pone.0005629.s021 (4.23 MB
XLS)
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PLoS ONE | www.plosone.org 11 May 2009 | Volume 4 | Issue 5 | e5629Dataset S3 Z-scores for individual hybridization computed
relative to five hybridizations of the original, unselected library.
Found at: doi:10.1371/journal.pone.0005629.s022 (3.58 MB
XLS)
Dataset S4 Z-scores for individual hybridizations computed
relative to six hybridization of the library cultured in the same
media (M9 with glucose and casamino acids) without antibiotics.
Found at: doi:10.1371/journal.pone.0005629.s023 (3.58 MB
XLS)
Dataset S5 Combined z-scores for all loci.
Found at: doi:10.1371/journal.pone.0005629.s024 (1.24 MB
XLS)
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